Company intelligence / Profile preview
Auransa
Palo Alto, California, United States of Americaauransa.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Phase 1
01
Overview
Auransa’s lead program AU409 is in a first-in-human clinical trial for liver cancer, with the first patient dosed both in the US and Asia. The company leverages its proprietary AI platforms to identify novel therapies targeting responsive patient populations. No published efficacy results yet.
- Therapeutic areas
- OtherOncology
- Modalities
- Small molecules (implied by focus on novel therapeutics and drug discovery)Monoclonal antibodies (patent topics)Antineoplastic drugs (patent topics)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Auransa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Auransa.